Synthekine

Synthekine

Biotechnology, 1505 Obrien Dr, Menlo Park, California, 94025, United States, 51-200 Employees

synthekine.com

  • twitter
  • LinkedIn

phone no Phone Number: 65********

Who is SYNTHEKINE

Synthekine is an engineered cytokine therapeutics company developing disease-optimized treatments. The company uses immunological insights to guide targeted protein engineering to generat...

Read More

map
  • 1505 Obrien Dr, Menlo Park, California, 94025, United States Headquarters: 1505 Obrien Dr, Menlo Park, California, 94025, United States
  • 2018 Date Founded: 2018
  • 51-200 Employees: 51-200
  • dollar-icon Revenue: $10 Million to $25 Million
  • tech-icon Active Tech Stack: See technologies

industries-icon Industry: Biotechnology

SIC SIC Code: 8621

checked-icon Does something look wrong? Fix it. | View contact records from SYNTHEKINE

Synthekine Org Chart and Mapping

Employees

Richard Murphy

Vice President Intellectual Property

Rooshabh Shah

Senior IT Manager of Applications

Navneet Ratti

Director, Translational Pathology

Andrew Morin

Principal Scientist, Computational Biology and Protein Design

Kai-Wen Huang

Senior Research Associate

Caitlin Prendes

Cmc Lead & Senior Director of Process Development

signout-image
You are signed out

Sign in to CIENCE GO Data to uncover contact details

crown-icon Free credits every month

Frequently Asked Questions Regarding Synthekine

Answer: Synthekine's headquarters are located at 1505 Obrien Dr, Menlo Park, California, 94025, United States

Answer: Synthekine's phone number is 65********

Answer: Synthekine's official website is https://synthekine.com

Answer: Synthekine's revenue is $10 Million to $25 Million

Answer: Synthekine's SIC: 8621

Answer: Synthekine has 51-200 employees

Answer: Synthekine is in Biotechnology

Answer: Synthekine contact info: Phone number: 65******** Website: https://synthekine.com

Answer: Synthekine is an engineered cytokine therapeutics company developing disease-optimized treatments. The company uses immunological insights to guide targeted protein engineering to generate transformative medicines for cancer and autoimmune disorders. Using the principles of cytokine partial agonism and immunological specificity, Synthekine designs differentiated therapeutics to be both safe and efficacious. Its lead programs have shown promising efficacy and tolerability in preclinical studies, and it is developing additional cytokine partial agonists that selectively modulate key pathways of the immune system.

Answer:

Premium Sales Data for Prospecting

  • Sales data across over 200M records

  • Up-to-date records (less decayed data)

  • Accurate Email Lists (real-world tested)

  • Powerful search engine and intuitive interface

lock icon Get Full Access